We are live on
!
Find out more
First Manhattan Portfolio holdings
AUM
$36.1B
1-Year Est. Return
11.5%
This Fund
S&P 500
This Quarter
Est. Return
+9.64%
1 Year Est. Return
+11.5%
3 Year Est. Return
+74.65%
5 Year Est. Return
+103.66%
10 Year Est. Return
+354.63%
AUM
$27.3B
AUM Growth
+$1.22B
(+4.7%)
Cap. Flow
-$932M
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
60.57%
Holding
1,588
New
70
Increased
176
Reduced
495
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$128M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$67.4M |
| 3 |
XIFR
XPLR Infrastructure LP
XIFR
|
+$63.8M |
| 4 |
UnitedHealth
UNH
|
+$57.4M |
| 5 |
Danaher
DHR
|
+$24.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$760M |
| 2 |
Amazon
AMZN
|
+$68.5M |
| 3 |
AbbVie
ABBV
|
+$54.2M |
| 4 |
PPLI
People Inc
PPLI
|
+$36.8M |
| 5 |
PNC Financial Services
PNC
|
+$29.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 44.09% |
| 2 | Technology | 18.28% |
| 3 | Healthcare | 10.34% |
| 4 | Consumer Discretionary | 7.89% |
| 5 | Communication Services | 5.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Regenxbio
RGNX
$655M
| $11M | 0.04% |
549,130
+101,400
| +23% | +$1.95M |
|
127
Altria Group
MO
$121B
| $10.8M | 0.04% |
239,497
-21,311
| -8% | -$965K |
|
128
Abbott
ABT
$177B
| $10.8M | 0.04% |
99,100
-118,844
| -55% | -$12.7M |
|
129
Green Brick Partners
GRBK
$3.06B
| $10.8M | 0.04% |
190,043
-97,357
| -34% | -$4.53M |
|
130
AXIS Capital
AXS
$8.49B
| $10.7M | 0.04% |
199,505
-23,530
| -11% | -$1.29M |
|
131
CSX Corp
CSX
$97.8B
| $10.6M | 0.04% |
310,789
-27,550
| -8% | -$871K |
|
132
Warner Bros
WBD
$65.1B
| $10.5M | 0.04% |
834,329
-24,947
| -3% | -$324K |
|
133
Jefferies Financial Group
JEF
$12.9B
| $10.4M | 0.04% |
314,026
-73,436
| -19% | -$2.29M |
|
134
Vanguard S&P Small-Cap 600 Value ETF
VIOV
$1.85B
| $10.4M | 0.04% |
126,603
-177
| -0.1% | -$14K |
|
135
Loews
L
$23.6B
| $10.4M | 0.04% |
174,798
-798
| -0.5% | -$46.2K |
|
|
LSXMK
136
DELISTED
Liberty Media Corporation Series C Liberty SiriusXM Common Stock
LSXMK
| $10.3M | 0.04% |
434,024
-32,855
| -7% | -$735K |
|
137
Sempra
SRE
$61.4B
| $9.86M | 0.04% |
135,468
-1,794
| -1% | -$135K |
|
138
Chubb
CB
$137B
| $9.85M | 0.04% |
51,161
-344
| -0.7% | -$67.4K |
|
139
Mine Safety
MSA
$6.72B
| $9.84M | 0.04% |
56,539
-1,986
| -3% | -$284K |
|
140
Orion
OEC
$395M
| $9.72M | 0.04% |
457,940
-62,215
| -12% | -$1.5M |
|
141
Wyndham Hotels & Resorts
WH
$5.47B
| $9.71M | 0.04% |
141,535
-10,805
| -7% | -$738K |
|
142
CVS Health
CVS
$137B
| $9.7M | 0.04% |
140,385
-9,487
| -6% | -$675K |
|
143
TriMas Corp
TRS
$1.44B
| $9.58M | 0.04% |
348,430
-50,000
| -13% | -$1.32M |
|
|
HTO
144
H2O America
HTO
$2.67B
| $9.56M | 0.04% |
136,378
-15,983
| -10% | -$1.21M |
|
145
SPDR Gold Trust
GLD
$130B
| $9.46M | 0.03% |
53,069
-9,751
| -16% | -$1.79M |
|
146
Colgate-Palmolive
CL
$72.1B
| $9.45M | 0.03% |
126,605
-12,554
| -9% | -$972K |
|
147
Qfin Holdings
QFIN
$1.6B
| $9.15M | 0.03% |
529,400
| – | – |
|
148
Motorola Solutions
MSI
$67.6B
| $8.99M | 0.03% |
30,640
-1,831
| -6% | -$524K |
|
149
TransAlta
TAC
$4.44B
| $8.84M | 0.03% |
944,152
-76,250
| -7% | -$715K |
|
150
Liberty Broadband Class C
LBRDK
$3.82B
| $8.73M | 0.03% |
121,059
-10,984
| -8% | -$849K |
|
Similar funds
SAM
First Manhattan's Q2 2023 Portfolio in Review
As of Q2 2023, First Manhattan held 1,588 positions worth $27.3B, up 4.7% from $26.1B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
First Manhattan withdrew a net $932M in Q2 2023, closing 161 positions and reducing 495 holdings. Its most notable exit was Enanta Pharmaceuticals, an estimated $10.7M position sold in full.
By sector, the portfolio is most concentrated in Financials at 44% of assets, down from 45% a quarter earlier, followed by Technology and Healthcare.
Against the trend, First Manhattan opened a new position in Mersana Therapeutics worth $1.87M.
- First Manhattan's largest Q2 2023 buy was Mersana Therapeutics: 22,784 shares worth $1.87M.
- First Manhattan added most to Thermo Fisher Scientific in Q2 2023, an estimated $128M increase.
- First Manhattan's biggest Q2 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $760M.
- First Manhattan fully exited Enanta Pharmaceuticals in Q2 2023, selling an estimated $10.7M.
- First Manhattan's ten largest holdings make up 61% of its $27.3B portfolio in Q2 2023.
- First Manhattan opened 70 new positions and closed 161 in Q2 2023.
- First Manhattan's portfolio value rose 4.7% quarter-over-quarter to $27.3B.
Based on First Manhattan's 13F filing for Q2 2023, filed 14 Aug 2023.